Video

Investigational oral agent noninferior to intravenous ertapenem for complicated UTIs

Author(s):

Urology Times staff

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Angela Talley, MD, discusses the background and notable findings of the recent New England Journal of Medicine paper, “Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection,” for which she served as senior author. Talley is senior vice president of Clinical Development at Spero Therapeutics.

      Related Videos
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jared S. Winoker, MD, answers a question during a Zoom video interview
      Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
      Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
      Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
      Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tips for PCPs on evaluating prostate cancer risk
      Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
      Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tailoring prostate cancer care for older adults
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: New strategies emerge for metastatic prostate cancer
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
      Related Content
      Prostate Gland - (BPH) Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
      December 26th 2024

      Top 10 BPH articles and videos of 2024

      Benjamin P. Saylor
      As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
      Crystal light - stock.adobe.com
      March 4th 2022

      Efficacy of batiraxcept/cabozantinib combo in clear cell RCC: Updated results

      Janelle Hart
      Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer
      February 7th 2022

      Dr. Lacouture on managing dermatological adverse events with apalutamide in prostate cancer

      Janelle Hart
      To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.
      How appropriate use criteria for PSMA-PET imaging optimize patient care
      February 2nd 2022

      How appropriate use criteria for PSMA-PET imaging optimize patient care

      Janelle Hart
      In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.
      Dr. Chee summarizes latest Optilume data in patients with urethral strictures
      November 9th 2021

      Dr. Chee summarizes latest Optilume data in patients with urethral strictures

      Urology Times staff
      "Certainly, the Optilume drug-coated balloon appears to be safe and effective in roughly two-thirds of patients at 3 years," said Justin Chee, MD.
      Dr. Declan G. Murphy describes the background of PSMA PET/CT in prostate cancer
      December 16th 2020

      Dr. Declan G. Murphy describes the background of PSMA PET/CT in prostate cancer

      Urology Times staff
      Murphy shares the backstory of how PSMA PET/CT imaging has emerged as a major advancement in the prostate cancer armamentarium.
      © 2025 MJH Life Sciences

      All rights reserved.